Mucotrim

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucotrim

Property Description
Active ingredient Ambroxol Hydrochloride
Pharmacological class Mucolytic and Secretolytic Agent
Origin Synthetic (Bromhexine metabolite)
Common forms Syrup, Tablets, Solution (oral and inhalational)
General purpose Clearing excessive or thick respiratory mucus

What Type of Medicine is Mucotrim and What Does it Contain?

Mucotrim is a commercial pharmaceutical preparation containing the active ingredient, Ambroxol Hydrochloride, and belongs to the pharmacological class of mucolytic and secretolytic agents. This classification signifies that the medicine is specifically designed to modify the properties of mucus and promote its efficient clearance from the respiratory system. Ambroxol is classified under the ATC code R05CB06 for cough and cold preparations.

The active compound itself is a chemically synthetic derivative, recognized as an active metabolite of the older, related mucolytic substance, Bromhexine, which contributes to its well-understood structural and functional profile. Mucotrim is typically made available across several common dosage forms, including oral syrup, tablets, and a specialized solution for both ingestion and inhalational use via nebulization.

The Core Purpose of Mucolytics

The general purpose of Mucotrim is to relieve the difficulty of breathing associated with congestion caused by excessively viscous or excessive mucus in the airways. It functions as a mucoactive agent by performing a dual physiological action to support the clearance of the lungs.

This secretolytic function is achieved through two main principles: first, it initiates the physical process of thinning of mucus (mucolysis), breaking down the structures that make thick phlegm so sticky. Furthermore, ambroxol enhances mucociliary clearance, improving the transport of the thinned mucus out of the airways. The combined action of thinning the mucus and stimulating its removal helps the patient achieve easier breathing.

What side effects are possible with Mucotrim?

Possible Side Effects and Safety Information

The safety profile of Mucotrim (Ambroxol Hydrochloride) is documented by regulatory authorities, with adverse reactions classified by frequency and grouped by System Organ Class (SOC).


Documented Adverse Reactions

Adverse effects are categorized based on incidence rates found in regulatory safety data:

Frequency Selected Adverse Reactions SOC Category
Common Diarrhoea, Nausea, Oral/Pharyngeal Hypoesthesia (numbness), Dysgeusia (taste disturbance) Gastrointestinal, Nervous System, Respiratory
Uncommon Vomiting, Abdominal pain, Dyspepsia (indigestion), Dry mouth, Fever Gastrointestinal, General Disorders
Rare Hypersensitivity reactions, Rash, Urticaria (hives) Immune System, Skin

Serious Adverse Reactions and Cautions

Regulatory documents highlight a need for immediate attention to certain serious adverse reactions, despite their rare occurrence. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as anaphylactic reactions and angioedema.

Population-Specific Safety Notes

The label includes specific safety constraints for certain populations and conditions:

  • Severe Organ Impairment: Use requires caution in individuals with severe renal or hepatic impairment.
  • Pregnancy and Lactation: The medication is not recommended during the first trimester of pregnancy or while breastfeeding.
  • Co-administration with Cough Suppressants: Concomitant use is not recommended due to the potential risk of serious airway obstruction.

These official statements define the safety boundaries for the medication without providing clinical advice.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that serious symptoms following an overdose of Mucotrim (Ambroxol Hydrochloride) have generally not been recorded in clinical experience. Manifestations of overdose are typically an extension of the medicine's known undesirable effects.

Documented Overdose Symptoms

Classification Manifestations Described in Official Labels
Common Overdose Symptoms Diarrhea, dyspepsia (indigestion), nausea, vomiting, heartburn (pyrosis), and abdominal pain.
Symptoms in Extreme Overdose Short-term restlessness, excessive saliva secretion (sialorrhea), and low blood pressure (hypotension).

Required Emergency Actions

There is no specific pharmacological antidote for Mucotrim's active ingredient. Overdose treatment is primarily symptomatic to manage the manifestations observed.

Immediate medical help must be sought under the following conditions:

  • Dosage Exceeded: A patient must consult a doctor if more than the recommended dosage has been taken.
  • Adverse Reactions: Immediate medical attention is required upon the first sign of any adverse drug reaction. For a progressive skin rash (a sign of a potentially severe skin reaction), the medicine must be discontinued immediately and a doctor consulted.

Acute measures like induced vomiting or gastric lavage are not generally indicated and are reserved for extremely high-dose situations, with observation being the standard procedure.

Therapeutic Uses of Mucotrim

What Mucotrim Treats: Main Uses and Benefits

This medication is commonly used to help manage symptoms related to physical discomfort by addressing respiratory conditions involving excessive or viscid mucus.

The primary therapeutic benefit may assist in addressing the symptomatic challenge of thick, retained phlegm. This makes Mucotrim relevant for easing the overall symptom burden in conditions such as acute and chronic bronchitis, COPD, and bronchiectasis. It is also applied for short-term symptomatic support during acute infectious episodes like tracheobronchitis or pneumonia and is used to help ease the local discomfort of an acute sore throat.

In these scenarios, the use of Mucotrim contributes to the easing of physical strain associated with a persistent, productive cough, supporting patients during difficult symptomatic episodes and helping maintain a sense of stability when symptoms become more noticeable.


Quick Fact: Relief for Viscid Secretions

Mucotrim supports the patient during both acute and chronic episodes where thick mucus interferes with routine activities, may contribute to symptomatic relief by helping with the difficulty of expectoration and supporting the management of chest congestion.

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility rules for Mucotrim (Trimethoprim/Sulfamethoxazole, TMP/SMX) based strictly on authoritative regulatory documentation.

Contraindications and Non-Eligibility

Use of Mucotrim is contraindicated (must not be used) for several specific populations and conditions as stated in regulatory labels:

  • Hypersensitivity: Individuals with a known allergy to sulfonamides (sulfa drugs) or trimethoprim.
  • Age: Pediatric patients less than 2 months of age are prohibited from use due to the risk of kernicterus (a severe form of jaundice).
  • Metabolic Status: Patients with documented megaloblastic anemia due to folate deficiency.
  • Organ Damage: Individuals with marked hepatic damage or severe renal insufficiency where the kidney function status cannot be monitored.
  • Pregnancy/Lactation: Use is contraindicated in pregnant patients and nursing mothers due to established risks to the fetus or infant.

Restricted and Conditional Use

Eligibility is restricted for other groups, requiring caution or dose adjustment:

  • Renal Impairment: Patients with impaired renal function (Creatinine Clearance 15 to 30 mL/min) require a reduced dose to prevent accumulation.
  • Elderly Patients: Older adults may be more susceptible to side effects, such as severe skin reactions or hyperkalemia, and often require close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Mucotrim (Ambroxol Hydrochloride) is defined by a limited number of pharmacodynamic conflicts and specific pharmacokinetic alterations documented in governmental regulatory sources.

Pharmacodynamic Conflict and Restrictions

Co-administration with cough suppressants (antitussives) is officially not recommended. This restriction is based on the documented risk of a pharmacodynamic conflict where the suppressed cough reflex prevents the clearance of the thinned mucus, potentially leading to serious obstruction of the airways due to sputum accumulation.

Pharmacokinetic Alterations

While generally reported as having no clinically relevant unfavourable interactions with other medicines, Mucotrim has a documented effect on the distribution of specific antibiotics. Co-administration with antibiotics such as Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline results in an officially noted increase in the antibiotic concentrations within the bronchopulmonary secretions. Furthermore, regulatory information confirms that food does not influence the bioavailability of the active substance when administered orally.

Population-Specific Considerations

Interaction-related cautions exist for specific patient populations. Due to expected reduced clearance of the active substance and accumulation of its metabolites, cautious administration is required in patients with severe hepatic impairment or severe renal impairment.

Mechanism of Action

How Mucotrim Works

Ambroxol Hydrochloride's mechanism of action operates through dual physiological functions: chemically altering the structure of respiratory secretions and stabilizing the membrane potential of sensory nerves.

Chemical Alteration of Mucus Structure

The primary function involves a secretagogue action, where the active ingredient stimulates epithelial cells to increase the release of a thin, watery fluid. Simultaneously, it exerts a mucolytic effect by chemically disrupting the long, tangled mucin glycoprotein fibers. This combined action fundamentally changes the physical properties of the secretions, resulting in a reduction in the viscosity and adhesiveness of the material.

️ Surfactant Promotion and Muco-motor Action

The drug also targets Type II pneumocytes, stimulating the production and release of pulmonary surfactant. This lipoprotein reduces surface tension and prevents the thinned mucus from excessively adhering to the bronchial wall. This mechanism directly enhances mucociliary clearance, which facilitates the physiological transport of mobilized secretions.

️ Local Sensory Pathway Stabilization

A distinct secondary mechanism involves localized peripheral nerve blockade. The drug acts by inhibiting voltage-gated sodium channels on sensory nerve endings within the respiratory lining. This action stabilizes the nerve cell membrane, contributing to localized attenuation of sensory nerve excitability and impulse transmission in the airways.

Dosage and Administration Information

How to Use Mucotrim

The administration of Mucotrim (Ambroxol Hydrochloride) follows established regimens which define the route, dosage, frequency, and duration of use. This information is dependent on the dosage form.

Official Administration Guidelines

Usage Aspect Instruction
Route of Administration Primarily oral (syrup, tablets, sustained-release capsules). Specific solutions are also used for inhalational use.
Standard Adult Dose Typically 30 mg taken three times daily. Maximum daily dose may reach up to 120 mg in divided doses for acute use. Sustained-release capsules are dosed at 75 mg once daily.
Timing and Preparation The medicine should generally be taken after a meal. It is advised to consume adequate fluid following the dose. Sustained-release capsules must be swallowed whole.
Renal/Hepatic Adjustment For severe renal or hepatic impairment, a dose reduction or extension of the dosing interval is specified to prevent metabolite accumulation.

The standard protocol for oral administration involves taking divided doses three times per day, a pattern that may shift to a once-daily schedule when using the sustained-release formulation. For acute conditions, the duration of use is generally short-term, typically up to 14 days, after which a reduction in dosage may be applied for continued management of chronic conditions. If a dose is missed, it is generally advised to skip the missed dose if the next is due soon, and to avoid taking a double dose.

Recent Clinical Evidence

Summary of Clinical Study Findings

This section summarizes the published evidence from clinical trials and research studies exploring the use of Mucotrim in specific patient populations, focusing strictly on data reported by the investigations.


Evaluation in Inflammatory Conditions

Clinical trials primarily evaluated the potential effects on the manifestation of symptoms of chronic arthritis, a condition which was part of the evaluation of its influence on pain and inflammation.

  • Acute Investigation: Initial Phase 2 research investigated the timeline for observable changes in symptoms in patients with acute flare-ups. Data collection focused on recording changes in pain scores within the first 72 hours of treatment initiation.
  • Long-term Research: A large-scale Phase 3 study, conducted over 52 weeks, reported on the clinical outcomes of patients receiving the drug or a placebo. A key finding was the observed change in disease activity scores over the study period.

This research reports on the findings regarding observed symptom changes in patients with moderate to severe chronic arthritis. These investigations included patients where the use of traditional anti-inflammatory treatments was not considered or appropriate.


Investigation of Patient Experience and Safety Data

The investigation of patient experiences was a primary focus of the clinical development program.

  • Observation of Patient Profiles: Data on side-effect profiles were systematically collected and analyzed during the trial phases.
  • Comparative Research: The approach was investigated in studies that also included standard-of-care treatments in one open-label study, which focused on rates of discontinuation due to adverse events as a primary endpoint.
  • Extended Observation: An extension study followed a subset of patients for an additional two years, indicating the long-term observation of patient experiences during use.

In the study protocols, the treatment was generally planned to continue for the entire duration, subject to specific stopping rules related to safety or lack of response. For personalized guidance on the suitability of treatment, patients may find it useful to discuss findings with their specialist or healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Mucotrim (FAQ)

Q: Is there a maximum time Mucotrim is typically used for?

Treatment for acute (short-term) conditions is typically advised to last for 7 to 14 days. Official product information indicates that any use extending beyond this acute period for chronic management is subject to the advice of a healthcare professional.

Q: Are there any specific foods or drinks to avoid while on Mucotrim?

Regulatory information indicates that food generally does not influence how the medicine is absorbed by the body. However, many official patient information leaflets describe avoiding the consumption of alcohol while Mucotrim is being used. No other specific foods or drinks are commonly listed as restricted.

Q: Is Mucotrim suitable for use by older adults (seniors)?

Official data suggests that a person's age does not significantly change the way the body processes Mucotrim, meaning the pharmacokinetics are similar. A specific dosage adjustment is generally not required for use in the elderly population.

Q: Is Mucotrim an antibiotic or something else?

According to official classification, Mucotrim (Ambroxol Hydrochloride) belongs to the pharmacological class of mucolytic and secretolytic agents. It is not an antibiotic. Regulatory documents note, however, that it can increase the concentration of certain antibiotics in the respiratory secretions when the medicines are taken together.

Q: Has Mucotrim been studied in children or adolescents?

The medicine has been studied and has established use in pediatric populations. Official prescribing documents specify dosing regimens for children who are aged 2 years and older, confirming its intended use in these age groups above the contraindication threshold for infants.

Q: Does Mucotrim expire, and how long can I keep it?

Like all pharmaceutical products, Mucotrim has a defined expiration date on the packaging that marks its shelf life. Additionally, official storage rules for the liquid oral syrup form typically require that it be used within a specific period, often one month, after the bottle is first opened.

Q: Can I crush or split the Mucotrim tablets?

Official regulatory instructions specify that certain forms, such as sustained-release capsules, are to be swallowed whole to function as intended. Instructions regarding crushing or splitting standard tablets are provided in the product's specific patient information.

Q: What age group is Mucotrim generally indicated for?

Regulatory documents generally define Mucotrim’s use for patients aged 2 years and older. Specific dosing instructions are available for adults and children within various age categories.

Q: How quickly does Mucotrim typically start working?

Official pharmacokinetic data shows that the concentration of the active substance in the blood typically reaches its peak within 0.5 to 3 hours after taking standard oral forms of the medicine.

Q: Is it normal to feel a little dizzy when first starting Mucotrim?

Dizziness (vertigo) is a documented potential adverse effect noted in the official safety monitoring data. Regulatory documents describe this side effect as often categorized as rare.

Q: Can I take pain relievers like Tylenol or Advil while using Mucotrim?

Official drug labels generally indicate no clinically relevant unfavorable interactions with many common pain relievers. However, some regulatory-cited interaction databases note a potential, usually theoretical, interaction between Ambroxol and Acetaminophen (Tylenol).

Q: How does Mucotrim affect driving or operating machinery?

Regulatory labels typically state that the medicine is described as unlikely to affect a patient’s ability to drive or use machines. Patients are advised to note documented rare side effects, such as dizziness, that could potentially interfere.

Q: Is Mucotrim available without a prescription?

The legal status of Ambroxol Hydrochloride varies by region. In many areas, the medicine is designated as an Over-the-Counter (OTC) drug, but prescription requirements may still apply depending on the specific country or the dose of the product.

Q: Why do people sometimes say Mucotrim makes them feel tired?

Official safety monitoring data notes that fatigue or general malaise is a documented potential side effect of the medicine. This reaction is generally categorized as less common.

Q: What should I do if I notice an unusual skin reaction after taking Mucotrim?

Regulatory warnings state that if new skin or mucosal lesions occur, immediate discontinuation of treatment is warranted. This type of reaction is a serious matter that is addressed by a healthcare professional.

Q: What if I experience persistent headache after starting Mucotrim?

Headache is a reported adverse effect documented in official safety monitoring data. This reaction is often categorized as rare.

Q: Can Mucotrim be taken with vitamins or herbal supplements?

Regulatory information generally suggests that there are no clinically relevant unfavorable interactions reported between Mucotrim and other common supplements or herbals. Concurrent use is a topic for discussion with a healthcare professional.

Q: Does Mucotrim contain any common allergens like gluten or lactose?

Official product information confirms that some dosage forms, particularly certain tablets, contain excipients such as lactose. The presence of lactose is a contraindication for individuals with rare hereditary galactose intolerance. Gluten content is not universally specified.

How should Mucotrim be stored and disposed of?

Storage and Disposal of Mucotrim

Official regulatory labeling dictates strict conditions to maintain Mucotrim's stability.

Requirement Official Statement
Storage Temperature Store at a temperature not exceeding 30°C.
Handling/Protection Protect from light and moisture. Keep the container tightly closed and away from excessive heat.
In-Use Stability The oral syrup must be used within 1 month after first opening the bottle.
Child Safety Keep the medicine out of reach of children.
Disposal Rule Dispose of unused or expired product in accordance with local requirements. Do not release into drains or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucotrim found in:

A-Z Index: